Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Safety and Tolerability of TAR-200 in Subjects With Muscle-Invasive Bladder Cancer Who Are Unfit for Radical Cystectomy

Bladder

The purpose of this study is to determine if TAR-200, an investigational drug-delivery system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are unfit for radical cystectomy (RC) during an 84-day induction period comprised of four consecutive 21-day dosing cycles.
Bladder
I
Keegan, Kirk
NCT03404791
VICCURO17103

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: